NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

You say NWBO has only added a quarter and 1.2 billion shares since 2017, as if that’s a punchline. But let’s walk through what those shares actually funded—and what’s been accomplished in that window.

NWBO’s Phase III trial wasn’t some boutique, single-site study. It was a multi-year, multi-country, randomized, double-blind, placebo-controlled trial—the gold standard in clinical research. It enrolled over 300 patients across the U.S., the U.K., and Germany, with rigorous oversight and data collection spanning nearly a decade. The trial was designed to test DCVax-L in newly diagnosed glioblastoma, one of the most aggressive and lethal brain cancers known to medicine.

This wasn’t a speculative pilot. It was a full-scale international trial with real-world endpoints, real regulatory scrutiny, and real survival data. And it culminated in a peer-reviewed publication in JAMA Oncology—a top-tier journal that doesn’t publish fluff. That alone puts NWBO in a different league than most dev-stage biotechs.

Since 2017, NWBO also submitted a regulatory application to MHRA, saw its indication expanded via the HDC list, underwent trial site inspections, and built out a GMP/HTA licensed manufacturing facility. That facility—Advent—wasn’t just developed. It was acquired, expanded, and validated to produce commercial-grade autologous cell therapies. Eden was created to future-proof the pipeline and embed manufacturing resilience. These weren’t distractions. They were strategic infrastructure moves.

And the dilution? It wasn’t toxic. It wasn’t debt-driven. It wasn’t institutional handcuffs. It was retail-funded, milestone-driven, and sequenced to preserve independence. NWBO didn’t dilute to survive—they diluted to build. To finish the trial. To construct Eden. To acquire and license Advent. To submit the application. To stay retail-owned.

Calling that “mismanagement” while ignoring the timestamped progress is like calling a rocket misaligned because it hasn’t landed yet. You’re measuring biotech by share count and quarterly revenue, while the real metric is regulatory velocity—and NWBO’s is accelerating.

As for “no shorts”? NWBO filed a lawsuit against market makers for spoofing and naked shorting. That’s not speculation—it’s litigation. And it’s backed by forensic trade data. The idea that there’s no short interest while the company sues over coordinated manipulation is laughable.

And patents? NWBO holds a robust portfolio covering dendritic cell manufacturing, antigen loading, and personalized immunotherapy protocols. These aren’t fluff filings. They’re foundational IP—positioned to protect DCVax-L and DCVax-Direct across multiple indications and geographies.

There are shorts. There are bad actors. And there’s a decade of coordinated FUD that collapses every time a milestone drops. You’re welcome to keep moving the goalposts. Just don’t expect the rest of us to pretend it’s analysis.

I am enthusiastic about my investment in NWBO. I know what I hold. You do too, which is why you continuously produce such fud 24/7.